Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
×

Get our best content in your email.

You are already a member! Please enter your password to sign in.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Gilead Sciences Inc GILD

Sector: Healthcare | Sub-Sector: Biotechnology

Gilead Sciences Inc is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors.
Price: $105.01 Volume: 22.3m
Change: +$4.50 % Change: +4.48%
Day High/Low: 106.34/102.50 52 Week High/Low: 116.83/76.630
Last Traded: May 01, 2015 12:15 Transaction Volume: 17
Open: 103.20 Previous Close: 100.51
Bid: Ask:
Bid Size: 0 Ask Size: 0
Market Cap: 155.7b Shares Out: 1.5b
PE Ratio: 14.3 Dividend Yield: 0.409485

Latest Bullboard Posts

  • Easier said than done

    0 stars

    Theoretically, to make money is easy, if you can stay ahead of the market, Warren Buffett happens to be the guy who can do that...

    2 stars


  • RE:Hopefully

    0 stars

    The stock dropped to $90 over 3 months ago when news of competition came out and the herd, as usual, got into the panic sell mode...

    2 stars


  • Flattering Forbes Article on GILD

    0 stars

    This might be old news but recently, a Forbes article looked at the flat revenue growth of Big Pharma (the top 15) and found...

    1 star


  • Can anyone explain the $234 value on this $98 stock?

    0 stars

    Sorry folks. Complete novice here (although I've been trading for years non consistently).  One tool I use (VST) rates this GILD stock at...

    1 star


  • Hopefully

    0 stars

    GILD will get back to $107 in the short term as it was before the negative rating a little while ago.  Once the hurdle is breached, I...

    2 stars